Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Olema Pharmaceuticals (OLMA) Income from Continuing Operations (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Income from Continuing Operations data on record, last reported at 53210000.0 in Q1 2026.

  • On a quarterly basis, Income from Continuing Operations fell 75.33% to 53210000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 185335000.0, a 43.74% decrease, with the full-year FY2025 number at 162474000.0, down 25.39% from a year prior.
  • Income from Continuing Operations reached 53210000.0 in Q1 2026 per OLMA's latest filing, down from 46074000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for OLMA hit a ceiling of 20051000.0 in Q2 2023 and a floor of 53210000.0 in Q1 2026.
  • A 5-year average of 32156235.29 and a median of 30422000.0 in 2024 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: plummeted 100.41% in 2022, then soared 39.01% in 2023.
  • Tracing OLMA's Income from Continuing Operations over 5 years: stood at 26246000.0 in 2022, then fell by 2.36% to 26865000.0 in 2023, then fell by 24.6% to 33474000.0 in 2024, then tumbled by 37.64% to 46074000.0 in 2025, then fell by 15.49% to 53210000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for OLMA at 53210000.0 in Q1 2026, 46074000.0 in Q4 2025, and 42229000.0 in Q3 2025.